Aptevo Therapeutics Inc.
Income Statement
| Line Item | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Sep 2020 | Jun 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.1M | $3.7M | $3.1M | $3.1M | $2.4M | $1.5M | $473.0K | $9.0M |
| Cost of Revenue | — | — | — | — | — | — | — | $6.1M |
| Gross Profit | — | — | — | — | — | — | — | $2.9M |
| Gross Margin | — | — | — | — | — | — | — | 32.1% |
| Operating Expenses | ||||||||
| Research & Development | $4.9M | $4.5M | $4.4M | $4.7M | $5.4M | $4.5M | $4.4M | $4.4M |
| SG&A Expense | $3.9M | $3.2M | $3.5M | $4.1M | $3.9M | $3.2M | $2.8M | $5.0M |
| Operating Income | $-5.6M | $-4.0M | $-4.8M | $-5.7M | $-6.9M | $-6.2M | $-6.8M | $-5.2M |
| Operating Margin | -180.2% | -110.2% | -153.4% | -184.0% | -284.5% | -426.9% | -1,439.1% | -57.2% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | $-6.9M | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-7.7M | $-6.3M | $-7.0M | $-7.9M | $-7.3M | $-6.8M | $-6.8M | $-8.2M |
| Net Margin | -247.2% | -171.1% | -226.0% | -255.0% | -299.7% | -464.2% | -1,438.3% | -90.5% |
| EPS (Basic) | $-0.78 | $-0.63 | $-0.72 | $-0.88 | $-0.82 | $-1.05 | $-1.05 | $-0.96 |
| EPS (Diluted) | $-0.78 | $-0.63 | $-0.72 | $-0.88 | $-0.82 | $-1.05 | $-1.05 | $0.04 |
| Shares Outstanding (Basic) | 9.9M | 9.8M | 9.8M | 9.1M | 8.9M | 6.5M | 6.5M | 6.5M |
| Shares Outstanding (Diluted) | 9.9M | 9.8M | 9.8M | 9.1M | 8.9M | 6.5M | 6.5M | 6.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |